Age-Related Macular Degeneration Clinical Trial
— SUDETESOfficial title:
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicentre Observational Study
NCT number | NCT06351670 |
Other study ID # | 1109/2024 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 2024 |
Est. completion date | July 2027 |
Verified date | April 2024 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with irreversible loss of vision on an individual-based level over 2 years. The main objectives of this study are: - Identify and quantify focal and global alterations in the retina in regard to disease progression. - Assess the individual risk of disease progression in intermediate AMD patients converting to advanced AMD based on imaging. - Specify the course of disease in regard to the sequence of events that lead to the conversion to advanced AMD - Enhance the ability to classify AMD using artificial intelligence in addition to traditional models. All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures: - Scanning Laser Fundus Photography - Color Fundus Photography (CFP) - Optical Coherence Tomography (OCT) - Optical Coherence Tomography Angiography (OCTA) Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out. No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.
Status | Not yet recruiting |
Enrollment | 500 |
Est. completion date | July 2027 |
Est. primary completion date | July 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 99 Years |
Eligibility | Inclusion Criteria: - Age: 55-99 years old - Early or intermediate AMD in at least one eye (drusen > 63 µm and/or any definite hyper- or hypopigmentary abnormalities with or without reticular pseudodrusen) - If both eyes are eligible, both eyes will be included in the cohort study. - Clear optical media and adequate pupillary dilation for imaging and functional testing. Exclusion Criteria: - Any surgical treatment of the eye within 3 months prior to baseline in the study eye - History of anti-VEGF treatment in the study eye before baseline - History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye - History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) = 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio > 0.9 - Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate/severe diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition - Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period - Presence of corneal decompensation, haze or scarring with an impact on BCVA - Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters. - Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen) - Presence of active macular neovascularization at baseline |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna | Centre Hospitalier Universitaire Dijon, Fundacion Clinic per a la Recerca Biomédica, Queen's University, Belfast, University Medical Centre Ljubljana, University of Zurich, Vista Klinik |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To characterise and quantify focal and global changes of the retina by retinal imaging to identify patients at risk for conversion to advanced AMD. | The correlation between biomarkers (independent variables) and progression will be assessed by linear mixed models or prospectively by Cox-regression models.
Artificial intelligence models will be applied to assess progression speed and predict local and global progression. Mixed Effects models will be calculated to estimate the association between independent variables, including the timepoint as an independent variable, on individual markers of progression (PR thinning and PR loss expansion). |
2 years | |
Secondary | To identify and quantify disease progression-related biomarkers | Longitudinal assessments of imaging biomarkers are performed in a descriptive manner. The following biomarkers will be evaluated in detail as independent variables:
Drusen volume/Refractile drusen (scale, nl) Subretinal Drusenoid Deposits (SDD) (scale, mm2) Hyperreflective Foci (HRF) (scale, nl) Thinning of outer retinal layers (PR thinning) (scale, µm) Loss of outer retinal layers (RPE and PR) (scale, mm2) PR loss/RPE loss ratio (scale, ratio) Other retinal biomarkers if relevant to the progression of intermediate AMD to advanced AMD The correlation between biomarkers (independent variables) and disease progression will be assessed by linear mixed models or prospectively by Cox-regression models. Mixed Effects models will be calculated to estimate the association between independent variables, including the timepoint as an independent variable, on individual markers of progression (PR thinning and PR loss expansion). |
2 years | |
Secondary | To evaluate monitoring of AMD progression assisted by AI algorithms | The following will be provided by AI-based image analysis of the GA Monitor (independent variables used to detect an event for the Cox-regression model):
RPE integrity loss (mm2) in the 1mm central area, 6mm area, and the respective relative change to previous visit PR integrity loss (mm2) in the 1mm central area, 6mm area, and the respective relative change to previous visit The following will be provided by AI-based image analysis of the Fluid Monitor (independent variables used to detect an event for the Cox-regression model): Intraretinal fluid volume (nl) in the 1mm central area, 6 mm area, and the respective relative change to previous visit Subretinal fluid volume (nl) in the 1mm central area, 6 mm area, and the respective relative change to previous visit Pigment epithelium detachment volume (nl) in the 1mm central area, 6mm area, and the respective relative change to previous visit |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |